5-氯-2-巯基苯并噁唑 | 22876-19-3

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶唑类
• 中文名称: 5-氯-2-巯基苯并噁唑
• 中文别名: 2-巯基-5-氯苯并恶唑；5-氯-2-巯基苯并恶唑；5-氯苯并[d]恶唑-2(3H)-硫酮；5-氯苯并恶唑-2-硫醇
• 英文名称: 5-chloro-2-mercaptobenzoxazole
• 英文别名: 5-chlorobenzo[d]oxazole-2-thiol；5-chloro-1,3-benzoxazole-2-thiol；5-chloro-2-benzoxazolethiol；2-mercapto-5-chlorobenzoxazole；5-chloro-benzooxazole-2-thiol；5‐chlorobenzo[d]oxazole‐2‐thiol；2-mercapto-5-chlorobenzoxazol；5-chloro-3H-1,3-benzoxazole-2-thione
• CAS: 22876-19-3
• 化学式: C₇H₄ClNOS
• mdl: MFCD00175241
• 分子量: 185.634
• InChiKey: BOBIZYYFYLLRAH-UHFFFAOYSA-N

物化性质

• 熔点：
  280-285 °C(lit.)
• 沸点：
  278.7±42.0 °C(Predicted)
• 密度：
  1.57±0.1 g/cm3(Predicted)
• 稳定性/保质期：
  如果按照规格使用和储存，则不会分解，未有已知危险发生。 应避免与强氧化剂接触。

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  53.4
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xn
• 危险类别码：
  R22,R36/37/38
• WGK Germany：
  3
• RTECS号：
  DM4760000
• 海关编码：
  2934999090
• 安全说明：
  S26,S36
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  请将药品存放在密闭、阴凉干燥的地方，并保持良好通风。

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : 5-Chloro-2-mercaptobenzoxazole
CAS-No. : 22876-19-3
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 [EU-GHS/CLP]
Acute toxicity, Oral (Category 4)
Skin irritation (Category 2)
Eye irritation (Category 2)
Specific target organ toxicity - single exposure (Category 3)
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Harmful if swallowed. Irritating to eyes, respiratory system and skin.
Label elements
Labelling according Regulation (EC) No 1272/2008 [CLP]
Pictogram
Signal word Warning
Hazard statement(s)
H302 Harmful if swallowed.
H315 Causes skin irritation.
H319 Causes serious eye irritation.
H335 May cause respiratory irritation.
Precautionary statement(s)
P261 Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
Safety data sheet available on request.
According to European Directive 67/548/EEC as amended.
Hazard symbol(s)
R-phrase(s)
R22 Harmful if swallowed.
R36/37/38 Irritating to eyes, respiratory system and skin.
S-phrase(s)
S26 In case of contact with eyes, rinse immediately with plenty of water and
seek medical advice.
S36 Wear suitable protective clothing.
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Formula : C7H4ClNOS
Molecular Weight : 185,63 g/mol
Component Concentration
5-Chloro-2-mercaptobenzoxazole
CAS-No. 22876-19-3 -

---

Section 4. FIRST AID MEASURES
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx), Sulphur oxides, Hydrogen chloride gas
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapors, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end uses
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: powder
Colour: white
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing Melting point/range: 280 - 285 °C - lit.
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
LD50 Oral - rat - 1.000 mg/kg
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
Inhalation - May cause respiratory irritation.
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation May be harmful if inhaled. Causes respiratory tract irritation.
Ingestion Harmful if swallowed.
Skin May be harmful if absorbed through skin. Causes skin irritation.
Eyes Causes serious eye irritation.
Signs and Symptoms of Exposure
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Additional Information
RTECS: DM4760000

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed
professional waste disposal service to dispose of this material. Dissolve or mix the material with a
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

Section 15. REGULATORY INFORMATION
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment
no data available

---

Section 16. OTHER INFORMATION
Further information
Copyright 2012 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

反应信息

• 作为反应物：
  描述：

  5-氯-2-巯基苯并噁唑 在 N,N-二甲基甲酰胺 草酰氯 、 potassium carbonate 作用下， 以 四氢呋喃 、 二氯甲烷 、 醋酸异丙酯 、 水 为溶剂， 反应 30.75h， 生成 苏沃雷生
  参考文献：
  名称：

  [EN] PROCESS FOR THE PREPARATION OF AN OREXIN RECEPTOR ANTAGONIST
  [FR] PROCÉDÉ DE PRÉPARATION D'UN ANTAGONISTE DES RÉCEPTEURS DES OREXINES

  摘要：

  本发明涉及制备一种二氮杂环庚烷化合物的方法，该化合物是促进睡眠受体的拮抗剂，并且在涉及促进睡眠受体的神经和精神障碍和疾病的治疗或预防中具有用途。本发明还涉及该二氮杂环庚烷化合物的晶体形式及其药物组合物。

  公开号：

  WO2012148553A1
• 作为产物：
  描述：

  4-氯-2-硝基苯酚 在 platinum on carbon 吡啶 、 氢气 作用下， 以 甲醇 为溶剂， 20.0 ℃ 、379.22 kPa 条件下， 反应 1.5h， 生成 5-氯-2-巯基苯并噁唑
  参考文献：
  名称：

  [EN] PIPERIDINECARBOXAMIDES AS MPGES - 1 INHIBITORS
  [FR] PIPÉRIDINECARBOXAMIDES EN TANT QU'INHIBITEURS DE MPGES - 1

  摘要：

  本发明涉及式(I)的哌啶羧酰胺，它们在医学上作为mPGES-1抑制剂用于治疗疼痛，包含它们的组合物，它们的制备过程以及用于这种过程的中间体。

  公开号：

  WO2011077313A1

文献信息

• Efficient Monofluoroalkylation of Thiophenols or Phenols with α-Bromo-α-Fluoroketones under Mild Conditions
  作者：Jingjing Wu、Fanhong Wu、Zhi Li、Mougui Fang、Yunli Liu、Yecheng Liu

  DOI：10.1055/a-1395-4788

  日期：2021.7

  nucleophilic substitution reaction between α-bromo-α-fluoroketones and thiophenols or phenols is reported for the synthesis of α-fluoro-β-ketosulfides or α-fluoro-β-ketone ethers in yields ranging from 78–93%. This method exhibits good functional group tolerance and a broad scope of nucleophilic substrates, including natural phenolic compounds.

  据报道，α-溴-α-氟代酮与硫酚或苯酚之间的有效亲核取代反应可合成α-氟代-β-酮硫醚或α-氟代-β-酮醚，产率为78-93％。该方法表现出良好的官能团耐受性和广泛的亲核底物，包括天然酚类化合物。
• Synthesis and anticancer activity evaluation of N-[4-(2-methylthiazol-4-yl)phenyl]acetamide derivatives containing (benz)azole moiety
  作者：Leyla Yurttaş、Yusuf Özkay、Gülşen Akalın-Çiftçi、Şafak Ulusoylar-Yıldırım

  DOI：10.3109/14756366.2013.763253

  日期：2014.4.1

  investigate their anticancer activity. The structure of the compounds was confirmed by IR, (1)H-NMR, and MS spectral data and elemental analyses. Anticancer effect of the compounds was evaluated against A549 and C6 tumor cell lines. MTT, analysis of DNA synthesis, acridine orange/ethidium bromide staining method and analysis of caspase-3 activation assays were performed for anticancer activity investigations

  合成了一类新型的新型噻唑-（苯并）唑衍生物以研究其抗癌活性。化合物的结构通过IR，（1）H-NMR和MS光谱数据以及元素分析确认。评价了化合物对A549和C6肿瘤细胞系的抗癌作用。进行了MTT，DNA合成分析，a啶橙/溴化乙锭染色方法和caspase-3活化分析，以进行抗癌活性研究。带有5-氯和5-甲基苯并咪唑基的化合物6f和6g显示出显着的抗癌活性。还观察到这些化合物将肿瘤细胞引导至凋亡途径的潜力，这是抗癌作用的前提。
• N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
  申请人：Rodgers James D.

  公开号：US20100298334A1

  公开（公告）日：2010-11-25

  The present invention relates to N-(hetero)aryl-pyrrolidine derivatives of Formula I: which are JAK inhibitors, such as selective JAK1 inhibitors, useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.

  本发明涉及式I的N-(杂)芳基吡咯烷衍生物： 这些是JAK抑制剂，如选择性JAK1抑制剂，在治疗JAK相关疾病方面具有用处，例如炎症和自身免疫性疾病，以及癌症。
• Benzoxazolamines and Benzothiazolamines: Potent, Enantioselective Inhibitors of Leukotriene Biosynthesis with a Novel Mechanism of Action
  作者：Edward S. Lazer、Clara K. Miao、Hin-Chor Wong、Ronald Sorcek、Denice M. Spero、Alex Gilman、Kollol Pal、Mark Behnke、Anne G. Graham

  DOI：10.1021/jm00033a008

  日期：1994.4

  phenylalanine with a cyclohexyl group greatly enhance potency. Several ester bioisosteres that retain potency and enantiomeric selectivity are described. Lead optimization culminated in (S)-N-[2-cyclohexyl-1-(2-pyridinyl)ethyl]-5-methyl-2-benzoxazolamine+ ++ (43b), IC50 0.001 microM. The compounds described are not inhibitors of 5-lipoxygenase but, rather, act at the level of arachidonic acid release.

  描述了一系列抑制白三烯（LT）生物合成的苯并恶唑胺和苯并噻唑胺类似物。最初的铅（S）-N-（苯并噻唑-2-基）苯丙氨酸乙酯（5a）在筛选程序中被发现，该程序可抑制Ca-离子载体-A23187诱导的人多形核白细胞释放LTB4（IC50 0.23 microM ）。通过结构修饰，确定了5-位上的疏水取代基以及苯丙氨酸的苯环被环己基取代极大地增强了效能。描述了几种保留效力和对映异构体选择性的酯类生物甾体。铅优化最终达到（S）-N- [2-环己基-1-（2-吡啶基）乙基] -5-甲基-2-苯并恶唑胺+ ++（43b），IC50 0.001 microM。所述化合物不是5-脂氧合酶的抑制剂，而是
• Analgesic Compounds, Compositions, and Uses Thereof
  申请人：Mannion James C.

  公开号：US20110224269A1

  公开（公告）日：2011-09-15

  The invention relates to compounds, compositions, and methods for diminishing pain in a subject in need thereof comprising administering the compounds and compositions herein described.

  这项发明涉及化合物、组合物和方法，用于减轻需要的受试者的疼痛，包括给予所述的化合物和组合物。